

The Tyrosine Kinase Csk Dimerizes through Its SH3 Domain

Nicholas M. Levinson^{1*}, Patrick R. Visperas¹, John Kuriyan^{1,2,3,4,5*}

1 Department of Molecular and Cell Biology, University of California, Berkeley, California, United States of America, **2** Department of Chemistry, University of California, Berkeley, California, United States of America, **3** California Institute for Quantitative Biosciences, University of California, Berkeley, California, United States of America, **4** Howard Hughes Medical Institute, University of California, Berkeley, California, United States of America, **5** Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, United States of America

Abstract

The Src family kinases possess two sites of tyrosine phosphorylation that are critical to the regulation of kinase activity. Autophosphorylation on an activation loop tyrosine residue (Tyr 416 in commonly used chicken c-Src numbering) increases catalytic activity, while phosphorylation of a C-terminal tyrosine (Tyr 527 in c-Src) inhibits activity. The latter modification is achieved by the tyrosine kinase Csk (C-terminal Src Kinase), but the complete inactivation of the Src family kinases also requires the dephosphorylation of the activation loop tyrosine. The SH3 domain of Csk recruits the tyrosine phosphatase PEP, allowing for the coordinated inhibition of Src family kinase activity. We have discovered that Csk forms homodimers through interactions mediated by the SH3 domain in a manner that buries the recognition surface for SH3 ligands. The formation of this dimer would therefore block the recruitment of tyrosine phosphatases and may have important implications for the regulation of Src kinase activity.

Citation: Levinson NM, Visperas PR, Kuriyan J (2009) The Tyrosine Kinase Csk Dimerizes through Its SH3 Domain. PLoS ONE 4(11): e7683. doi:10.1371/journal.pone.0007683

Editor: Bostjan Kobe, University of Queensland, Australia

Received: September 7, 2009; **Accepted:** October 5, 2009; **Published:** November 4, 2009

Copyright: © 2009 Levinson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Howard Hughes Medical Institute (www.hhmi.com). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: kuriyan@berkeley.edu

‡ Current address: Department of Chemistry, Stanford University, Stanford, California, United States of America

Introduction

Members of the Src family of protein tyrosine kinases, such as c-Src, Lck, Fyn and Hck, are key players in many signalling pathways that regulate cell growth, proliferation and motility [1]. Src kinase activity is tightly controlled through phosphorylation at two regulatory sites, Tyr 416 and Tyr 527 (chicken c-Src numbering) [2]. Autophosphorylation of the Src family kinases on Tyr 416, located within a central regulatory element in the kinase domain known as the activation loop, increases activity by stabilizing the kinase domain in a conformation that promotes catalysis [3]. In contrast, the phosphorylation of Tyr 527 in the C-terminal tail of the Src family kinases by Csk (C-terminal Src Kinase) results in the intramolecular engagement of the tail by the Src Homology 2 (SH2) domain and the concomitant docking of the Src Homology 3 (SH3) domain onto the SH2-kinase linker, which together stabilize the kinase domain in an inactive conformation [4,5,6,7,8]. Full inactivation of the Src family kinases consequently requires both dephosphorylation of the activation loop and phosphorylation of the C-terminal tail [9].

The kinase domain of Csk is responsible for the recognition of the Src family kinases as its specific substrates, resulting in phosphorylation of the C-terminal tail [10]. The ability of Csk to regulate Src kinase activity in vivo also depends on both the SH2 and SH3 domains of Csk [11,12]. Unlike the Src family kinases, Csk is not constitutively membrane-localized, and the SH2 domain is required for the recruitment of Csk to the plasma

membrane. Several different proteins have been shown to recruit Csk through its SH2 domain, including paxillin [12] and the transmembrane adapter protein Cbp (Csk-binding protein) [13].

The SH3 domain of Csk interacts with several tyrosine phosphatases [14,15]. In T-cells, Csk associates with the tyrosine phosphatase PEP, which dephosphorylates the activation loop of the Src family kinase Lck [16]. The association of Csk and PEP provides for a coordinated downregulation of Lck through simultaneous phosphorylation of the C-terminus and dephosphorylation of the activation loop. Csk has also been reported to associate with the widely expressed tyrosine phosphatase PTP-PEST in non-haematopoietic cells [15], suggesting that such a coordinated mechanism may be widespread.

Pursuing the observation that Csk is dimeric at high protein concentration (i.e., ~1 mg/ml or greater) in vitro [17], we have discovered that Csk dimerizes in a manner that is incompatible with the binding of ligands to the SH3 domain. By interfering with the recruitment of tyrosine phosphatases, Csk dimerization could serve to modulate the degree of activation loop phosphorylation and activity of the Src family kinases.

Results and Discussion

Dimerization of Csk Requires the SH3 Domain

Csk protein is dimeric in solution, as indicated by analytical ultra-centrifugation and gel filtration chromatography [17], but the molecular nature of this dimer interaction is unknown. We

performed size exclusion chromatography with different constructs of Csk (see figure 1), and found that while the full-length protein (Csk_{FL}) migrates as a dimer by size exclusion, the removal of the SH3 domain (Csk_{SH2KD}) or the SH3 and SH2 domains (Csk_{KD}) resulted in proteins that no longer appear to dimerize and instead elute as apparent monomers by gel filtration (figure 1). This suggests that the SH3 domain of Csk is involved in the dimer interface.

The SH3 Domain Mediates Dimerization of Csk

Analysis of the crystal packing interactions in the crystal structure of full-length Csk [17] reveals an interaction that is consistent with the requirement of the SH3 domain for dimerization. The crystal structure contains 6 molecules of Csk in the asymmetric unit, and pairs of SH3 domains form symmetric interactions consistent with dimer formation. The interaction buries a total of 946 Å² of surface area between the two domains and includes several hydrophobic contacts (figure 2). Despite the fact that the six molecules of Csk in the asymmetric unit of this structure are in somewhat different conformations, the SH3 domains of each molecule participate in identical dimer interactions with adjacent molecules in the crystal lattice. Intriguingly the same interaction is also observed in the crystal structure of the isolated SH3 domain of Csk [18], suggesting that this interaction might be physiologically relevant.

We mutated the surface of the SH3 domain of Csk that mediates the putative dimer interaction extensively, and assessed the ability of the mutant proteins to dimerize by size exclusion chromatography (figure 2). Of the six mutant proteins tested, five migrate as monomers, while the protein bearing the Asn 63 Ala

mutation migrates mostly as a dimer, with a small shoulder corresponding to a monomer species. This is consistent with the observation from the structure that Asn 63 makes only very weak interactions in the interface (i.e., it does not form tight hydrogen bonds with neighboring residues). These results indicate that the dimers of Csk observed in solution rely on the SH3–SH3 interface seen in the crystal structures of full-length Csk and the isolated SH3 domain.

The Csk Dimer Is Incompatible with the Binding of Ligands to the SH3 Domain

SH3 domains bind to peptides containing PXXP sequences that readily form polyproline type II helices [19,20,21]. The SH3 domain of Csk binds to a polyproline motif (referred to as 3BP1, for SH3 binding peptide 1) in the C-terminus of the protein tyrosine phosphatase PEP [22], and the recruitment of PEP and Csk to the membrane is required for inhibition of T-cell signaling [16]. The 3BP1 motif of PEP binds to Csk with an unusually high affinity compared to most SH3-peptide interactions, and the high affinity interaction depends on a hydrophobic motif C-terminal to the polyproline motif [22]. The solution structure of the SH3 domain of Csk in complex with a peptide comprising the 3BP1 motif demonstrated that in addition to the canonical polyproline helix-SH3 interaction, the hydrophobic residues in the 3BP1 motif also form interactions with the SH3 domain [23].

In the Csk SH3-SH3 homodimer the ligand binding surface on both SH3 domains is occluded. This is demonstrated by a comparison between the Csk residues involved in the SH3-SH3 dimer interface with those involved in binding the 3BP1 peptide (figure 3). It is therefore expected that the formation of the SH3-SH3 dimer would prevent the binding of the 3BP1 peptide and vice versa. This is consistent with the observation that the addition of the 3BP1 peptide to the isolated SH3 domain prevents oligomerization of the SH3 domain [23]. Interestingly, the secondary binding site for the hydrophobic residues of 3BP1 is not occluded by the SH3-SH3 dimer (figure 3). It is possible that PEP might still be able to interact weakly with a Csk dimer through this secondary binding site, although the binding of other phosphatases, such as PTP-PEST, to the Csk SH3 domain would be completely blocked by the formation of the dimer.

A Speculative Model for the Functional Role of the Csk Homodimer

The recruitment of both Csk and PEP to the plasma membrane is critical for the inhibition of T-cell signaling [16]. The observation that the Csk homodimer should interfere with the binding of the PEP phosphatase to the SH3 domain suggests that the two interactions may compete in cells. The dimerization of Csk could therefore have a profound influence on the recruitment of phosphatases to sites of Src kinase activity, with important implications for the regulation of the Src kinases.

The 3BP1 element of PEP interacts with the SH3 domain of Csk with a K_D value of ~800 nM [23]. The affinity of the SH3-SH3 interaction is unknown, but our gel filtration data indicate that the dimer is formed at 20 μM. The question therefore remains whether the SH3-SH3 interaction can effectively compete with the relatively high affinity SH3-PEP interaction. The recruitment of proteins to the cell membrane may increase their effective concentration by as much as 1000-fold [24], allowing interactions that are weak in solution to play a significant role [25]. The phosphorylated cytoplasmic domain of Cbp is known to form oligomers that bind multiple molecules of Csk [26], potentially providing a platform on which Csk molecules are




Figure 1. The SH3 domain of Csk is required for dimerization. A) The constructs used in this paper. B) The results of size exclusion chromatography performed with the constructs shown in A. The elution volumes of molecular weight standards are indicated by black arrows. doi:10.1371/journal.pone.0007683.g001





Figure 2. The Csk SH3-SH3 dimer. A) A representative SH3-SH3 dimer from the crystal structure of full-length Csk (PDB code: 1K9A). Residues in the interface are highlighted. B) The results of size exclusion chromatography performed with constructs of Csk bearing mutations in the putative dimer interface.

doi:10.1371/journal.pone.0007683.g002

recruited in close proximity. This could further promote the formation of dimers, resulting in the displacement of the phosphatase, and allowing for the activation of Lck through

autophosphorylation. In this light it would be interesting to see how mutations that disrupt the Csk SH3-SH3 dimer interface affect signaling in cells.




Figure 3. The Csk SH3-SH3 dimer is incompatible with the binding of ligands to the SH3 domain. The solution structure of the SH3 domain of Csk in complex with the phosphatase-derived peptide PEP-3BP1 (pdb code 1JEG). The residues of Csk that are involved in the SH3-SH3 dimer interface are highlighted by sticks and black dots as in Figure 2. doi:10.1371/journal.pone.0007683.g003

Methods

Expression and Purification of Csk Constructs

The constructs of human Csk, Csk_{FL} (residues 1–450), Csk_{SH2KD} (residues 68–450) and Csk_{KD} (residues 187–450) were expressed in bacteria and purified as described [10]. The SH3 domain mutations were prepared using the Quikchange protocol (Statagene) and verified by DNA sequencing.

Gel Filtration Chromatography

Purified Csk proteins were subjected to analytical gel filtration using a Superdex S200 column (GE Healthcare) or SMART S200 column (GE Healthcare). Column calibration was performed

using molecular weight standards (Ferritin, Catalase, GST, Ribonuclease).

Acknowledgments

We thank Meindert Lamers for help with size exclusion chromatography, and Art Weiss for helpful discussions.

Author Contributions

Conceived and designed the experiments: NML. Performed the experiments: NML PV. Analyzed the data: NML PV JK. Wrote the paper: NML.

References

1. Brown MT, Cooper JA (1996) Regulation, substrates and functions of src. *Biochim Biophys Acta* 1287: 121–149.
2. Takeya T, Hanafusa H (1983) Structure and sequence of the cellular gene homologous to the RSV src gene and the mechanism for generating the transforming virus. *Cell* 32: 881–890.
3. Yamaguchi H, Hendrickson WA (1996) Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. *Nature* 384: 484–489.
4. Sicheri F, Moarefi I, Kuriyan J (1997) Crystal structure of the Src family tyrosine kinase Hck. *Nature* 385: 602–609.
5. Xu W, Harrison SC, Eck MJ (1997) Three-dimensional structure of the tyrosine kinase c-Src. *Nature* 385: 595–602.
6. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, et al. (1999) Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. *Mol Cell* 3: 639–648.

7. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC (1999) Crystal structures of c-Src reveal features of its autoinhibitory mechanism. *Mol Cell* 3: 629–638.
8. Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H (1991) CSK: a protein-tyrosine kinase involved in regulation of src family kinases. *J Biol Chem* 266: 24249–24252.
9. Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee CH, et al. (1997) Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. *Nature* 385: 650–653.
10. Levinson NM, Seeliger MA, Cole PA, Kuriyan J (2008) Structural basis for the recognition of c-Src by its inactivator Csk. *Cell* 134: 124–134.
11. Cloutier JF, Chow LM, Veillette A (1995) Requirement of the SH3 and SH2 domains for the inhibitory function of tyrosine protein kinase p50csk in T lymphocytes. *Mol Cell Biol* 15: 5937–5944.
12. Sabe H, Hata A, Okada M, Nakagawa H, Hanafusa H (1994) Analysis of the binding of the Src homology 2 domain of Csk to tyrosine-phosphorylated proteins in the suppression and mitotic activation of c-Src. *Proc Natl Acad Sci U S A* 91: 3984–3988.
13. Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, et al. (2000) Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. *Nature* 404: 999–1003.
14. Cloutier JF, Veillette A (1996) Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. *EMBO J* 15: 4909–4918.
15. Davidson D, Cloutier JF, Gregorieff A, Veillette A (1997) Inhibitory tyrosine protein kinase p50csk is associated with protein-tyrosine phosphatase PTP-PEST in hemopoietic and non-hemopoietic cells. *J Biol Chem* 272: 23455–23462.
16. Cloutier JF, Veillette A (1999) Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. *J Exp Med* 189: 111–121.
17. Ogawa A, Takayama Y, Sakai H, Chong KT, Takeuchi S, et al. (2002) Structure of the carboxyl-terminal Src kinase, Csk. *J Biol Chem* 277: 14351–14354.
18. Borchert TV, Mathieu M, Zeelen JP, Courtneidge SA, Wierenga RK (1994) The crystal structure of human CskSH3: structural diversity near the RT-Src and n-Src loop. *FEBS Lett* 341: 79–85.
19. Lim WA, Richards FM, Fox RO (1994) Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains. *Nature* 372: 375–379.
20. Feng S, Chen JK, Yu H, Simon JA, Schreiber SL (1994) Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. *Science* 266: 1241–1247.
21. Kuriyan J, Cowburn D (1997) Modular peptide recognition domains in eukaryotic signaling. *Annu Rev Biophys Biomol Struct* 26: 259–288.
22. Gregorieff A, Cloutier JF, Veillette A (1998) Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk). *J Biol Chem* 273: 13217–13222.
23. Ghose R, Shekhtman A, Goger MJ, Ji H, Cowburn D (2001) A novel, specific interaction involving the Csk SH3 domain and its natural ligand. *Nat Struct Biol* 8: 998–1004.
24. Kholodenko BN, Hoek JB, Westerhoff HV (2000) Why cytoplasmic signalling proteins should be recruited to cell membranes. *Trends Cell Biol* 10: 173–178.
25. Kuriyan J, Eisenberg D (2007) The origin of protein interactions and allostery in colocalization. *Nature* 450: 983–990.
26. Takeuchi S, Takayama Y, Ogawa A, Tamura K, Okada M (2000) Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk. *J Biol Chem* 275: 29183–29186.